Demonstration of receptor-mediated targeting of nanoparticles to specific organs and/or cell types is an integral aim in many bionanomedicine development projects. However, engagement of targeted receptors with ligands on nanocarriers, which is the cornerstone of the active targeting concept, is challenging to study under biologically relevant conditions and thus often stays overlooked. In this work, we utilize an in-house established bioassay for in vitro targetability validation of mesoporous silica nanoparticles (MSNs), functionalized with high-affinity peptide ligands to somatostatin receptors via protective group chemistry, ensuring the correct orientation of the peptide's pharmacophore. We demonstrate that targeted nanoparticles, but not scrambled peptide-decorated counterparts, specifically engage the targeted receptors in living cells in culture media containing serum protein. The importance of being able to exclude false positives originating from the premature detachment of targeting peptides from the MSNs is highlighted.
The authors gratefully acknowledge support from the following sources: European Community Mobility Programme EMA2 (#372117-1-2012-1-FI-ERAMUNDUS-EMA21; VP), Turku Doctoral Programme of Molecular Medicine (VP), K. Albin Johanssons stiftelse (VP), Ida Montinin Säätiö (VP), Pentti and Tyyni Ekbom Foundation (VP), Instrumentariumin Tiedesäätiö (VP), DFG-funded CRC 1279 project Exploiting the human peptidome for novel antimicrobial and anticancer agents (MG and ML).
|Pentti and Tyyni Ekbom Foundation
|Turku Doctoral Programme of Molecular Medicine
- mesoporous silica
- nanoparticle corona
- somatostatin receptor